[{"id":"aecf3ac5-9504-4f3a-9a5f-7cc5aaedb65d","acronym":"NCI-2019-03212","url":"https://clinicaltrials.gov/study/NCT03965689","created_at":"2021-01-18T19:30:37.082Z","updated_at":"2024-07-02T16:35:02.796Z","phase":"Phase 2","brief_title":"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy","source_id_and_acronym":"NCT03965689 - NCI-2019-03212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression","tags":["BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2024-05-17"}]